Physician profile
Imran Sheikh
NPI 1982848750
$4,845.66
in general payments reported to CMS, 2019-2025
30 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $382 · 2021: $1,133 · 2022: $1,102 · 2023: $730 · 2024: $599 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,420.35 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $520.79 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.98 | 2019-2024 | Trulance, Xifaxan |
| Celgene Corporation | $302.32 | 2021-2024 | Zeposia |
| Abbott Laboratories | $158.34 | 2022 | |
| Janssen Biotech, INC. | $129.31 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Boston Scientific Corporation | $121.95 | 2019 | |
| Ferring Pharmaceuticals INC. | $93.72 | 2019-2023 | Clenpiq |
| Madrigal Pharmaceuticals | $67.31 | 2025 | Rezdiffra |
| Pfizer INC. | $60.63 | 2022-2024 | |
| Daiichi Sankyo INC. | $53.50 | 2021-2022 | |
| Ardelyx, INC. | $51.47 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $43.43 | 2022-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $41.48 | 2021-2022 | |
| Acclarent, INC | $41.47 | 2023 | Trudi Nav Cable |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.01 | 2025 | Lifevest |
| Nestle Healthcare Nutrition INC. | $37.08 | 2021 | |
| Genzyme Corporation | $35.09 | 2023-2025 | |
| Redhill Biopharma INC. | $33.18 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.76 | 2025 | Dupixent |
| Vivus LLC | $31.60 | 2022 | |
| Braintree Laboratories, INC. | $29.47 | 2021 | |
| Glaxosmithkline, LLC. | $25.10 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.17 | 2024 | Voquezna |
| Pacira Pharmaceuticals Incorporated | $22.13 | 2022 | |
| Evoke Pharma, INC. | $18.53 | 2023 | Gimoti |
| Gilead Sciences, INC. | $17.98 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $16.84 | 2021 | |
| Celltrion USA INC. | $16.08 | 2025 | Vegzelma |
| Organon LLC | $8.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.